The global depression treatment market, valued at USD 11 billion in 2024, is poised for steady growth, projected to reach USD 18.3 billion by 2034 at a CAGR of 5.2%. This expansion is driven by ...

Three of the RSU grants vests ratably in equal installments on the first, second, and third anniversaries of the grant date, and one of RSU grants vests ratably in equal installments on the second, ...

Ketamine advertisements are popping up all around us. With few regulations in place, might we be witnessing another opioid ...

The latest issues of two American Psychiatric Association journals, The American Journal of Psychiatry and Psychiatric Services, are now available online.

Stifel initiates Compass Pathways with a buy, highlighting psychedelics' therapeutic potential. Read more here.

Jason Najum talks to Srinivas Rao, CEO of Atai Life Sciences, a biotech company focused on mental health and psychedelic compounds.

Treatment-resistant depression complicates care, defying standard treatments, but new therapies are on the horizon, offering hope for more effective treatment options.

Ketamine, a dissociative anesthetic, has carved itself a spot in the world of mental health care over the past two decades.

China: A recent randomized clinical trial has highlighted the potential benefits of intraoperative esketamine in reducing ...

Intraoperative esketamine infusion significantly reduced the incidence of postpartum depression (PPD) at 6 weeks post partum ...

The American Psychiatric Association (APA) named Mark Rapaport, MD, of the University of Utah, as the medical society's next ...

Major depressive disorder (MDD) is a leading cause of disability worldwide, with a significant proportion of patients (10-20%) progressing to treatment-resistant depression (TRD).